Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, these observations support LOX-1 inhibition as a target for prevention of cardiovascular disease and suggest that this may be used to address the residual risk in patients receiving current state-of-the-art preventive treatment. The gene discussed is OLR1; the disease is cardiovascular disorder.